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Statement of translational relevance: 26 
Temozolomide and radiotherapy are the adjuvant standard of care for patients with 27 
glioblastoma. This manuscript demonstrates an unprecedented role of the NKG2D-28 
dependent immune pathway for the efficacy of these anti-cancer therapies against 29 
glioblastoma. Both treatment modalities induce immune-stimulatory NKG2D ligands 30 
also in unfavorable but clinically relevant settings of MGMT overexpression, TMZ 31 
resistance and at tumor recurrence. This promotes the role of the NKG2D system as an 32 
attractive immunotherapeutic target in glioblastoma at primary diagnosis and at 33 
recurrence. Furthermore, it provides a strong rationale for future combination studies of 34 
conventional radiochemotherapy and NKG2D-based immunotherapy.  35 
 36 
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Abstract 52 
Purpose: NKG2D is a potent activating immune cell receptor and glioma cells express 53 
the cognate ligands (NKG2DL). These ligands are inducible by cellular stress and 54 
temozolomide (TMZ) or irradiation (IR), the standard treatment of glioblastoma, could 55 
affect their expression. However, a role of NKG2DL for the efficacy of TMZ and IR has 56 
never been addressed. 57 
Experimental Design: We assessed the effect of TMZ and IR on NKG2DL in vitro and in 58 
vivo in a variety of murine and human glioblastoma models including glioma-initiating 59 
cells and a cohort of paired glioblastoma samples from patients before and after 60 
therapy. Functional effects were studied with immune cell assays. The relevance of the 61 
NKG2D system for the efficacy of TMZ and IR was assessed in vivo in syngeneic 62 
orthotopic glioblastoma models with blocking antibodies and NKG2D knockout mice. 63 
Results: TMZ or IR induced NKG2DL in vitro and in vivo in all glioblastoma models and 64 
glioblastoma patient samples had increased levels of NKG2DL after therapy with TMZ 65 
and IR. This enhanced the immunogenicity of glioma cells in a NGK2D-dependent 66 
manner, was independent from cytotoxic or growth inhibitory effects, attenuated by O6-67 
methylguanine-DNA-methyltransferase (MGMT) and required the DNA 68 
damage response. The survival benefit afforded by TMZ or IR relied on an intact 69 
NKG2D system and was decreased upon inhibition of the NKG2D pathway. 70 
Conclusion: The immune system may influence the activity of convential cancer 71 
treatments with particular importance of the NKG2D pathway in glioblastoma. Our data 72 
provide a rationale to combine NKG2D-based immunotherapies with TMZ and IR. 73 
 74 
 75 
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Introduction 76 
Glioblastoma is the most common malignant primary brain tumor in adults with a dismal 77 
prognosis (1). The first-line treatment in patients below 70 years of age includes surgical 78 
resection as feasible, radiotherapy and concomitant and maintenance chemotherapy 79 
with temozolomide (TMZ), an alkylating agent that induces DNA damage (2, 3). In 80 
addition to these treatment modalities, several promising immunotherapeutic 81 
approaches against glioblastoma are currently being evaluated (4, 5). These efforts are 82 
supported by the observation that glioma cells express molecules that allow for an 83 
interaction with cells of the immune system such as major histocompatibility complex 84 
(MHC) class I and class II molecules (6) as well as MHC class I-like ligands which bind 85 
to the activating immune cell receptor natural-killer group 2 member D (NKG2D) (7). In 86 
humans, NKG2D ligands (NKG2DL) comprise the MHC class I-related chains (MIC) A 87 
and B (MICA, MICB) and the UL16 binding proteins (ULBP) 1–6 (8). These ligands are 88 
expressed on human glioma cells in vitro (9) and in vivo (10) as well as on glioma-89 
initiating cells (GIC), a subpopulation of cells with stem cell properties (11, 12). In mice, 90 
NKG2DL comprise the retinoic acid early inducible-1 (RAE-1) proteins, members of the 91 
H60 family (H60a, H60b, H60c) and the murine UL16-binding protein like transcript-1 92 
(MULT-1) which are also expressed by mouse glioma cells (9, 13). All NKG2DL bind to 93 
the NKG2D receptor which is one of the major activating receptors on natural killer (NK) 94 
cells (8). In addition to NK cells, this receptor is constitutively expressed on NKT cells, 95 
αȕ CD8 T cells and Ȗδ T cells (8, 14). Furthermore, its expression is induced on CD4 T 96 
cells by tumor necrosis factor (TNF)-α and interleukin (IL)-15 (15, 16). However, various 97 
glioma-derived humoral and cellular immunosuppressive mechanisms preclude an 98 
efficient anti-tumor immune response, including the expression of transforming growth 99 
factor (TGF)-ȕ (17), prostaglandin E2 (PGE2) (18), IL-10 (19), growth and differentiation 100 
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factor (GDF)-15 (20), lectin-like transcript 1 (LLT1) (21), indoleamine 2,3-dioxygenase 101 
(IDO) (22), programmed death ligand 1 (PD-L1) (23), as well as the presence of 102 
immunosuppressive regulatory T cells (Tregs) (24) and M2-polarized microglia (25). 103 
Enhancing the immunogenicity of glioma cells may be achieved either by inhibition of 104 
these immunosuppressive mechanisms (26) or by promoting immune activating signals 105 
such as the NKG2DL (27). Since various cellular stress stimuli including malignant 106 
transformation of cells or DNA damage can induce NKG2DL (8), we explored whether 107 
TMZ or irradiation (IR) as part of the standard treatment for glioblastoma increase 108 
NKG2DL levels on glioma cells and whether this promotes their immunogenicity. We 109 
also defined the molecular mechanisms underlying the TMZ- and IR-induced NKG2DL 110 
expression in glioma cells. Finally, we investigated the significance of the NKG2D 111 
system for the survival benefit gained with TMZ and IR in several immunocompetent 112 
mouse glioma models. 113 
  114 
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Material and Methods 115 
Cells and materials 116 
The human glioma cell lines LN-18 and LN-229 were kindly provided by Dr. N. de 117 
Tribolet (Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland). LN-229-R 118 
cells were generated by repetitive exposure to TMZ resulting in a shift of the EC50 (28). 119 
Generation of LNT-229_MGMT and LNT-229_neo (29) and LN-18_shMGMT and LN-120 
18_puro cells (30) has been described. SMA-560 glioma cells were obtained from Dr. D. 121 
Bigner (Duke University Medical Center, Durham, North Carolina, USA) and GL-261 122 
were obtained from the National Cancer Institute (Frederick, Maryland, USA). SMA-123 
560_Turbo650 and GL-261_NirFP were created by lentiviral transduction of GL-261 and 124 
SMA-560 cells with plasmids encoding near-infrared fluorescent proteins Turbo650 and 125 
NirFP (Evrogen, Moscow, Russia) and selection by fluorescence-activated cell sorting 126 
(FACS). Adherent cell lines were maintained in Dulbecco's Modified Eagle Medium 127 
(DMEM, Invitrogen, Basel, Switzerland), containing 2 mM L-glutamine (Gibco Life 128 
Technologies, Paisley, UK), and 10% fetal calf serum (FCS, Biochrom KG, Zug, 129 
Switzerland). The GIC cell lines S-24 and ZH-305 were generated from human 130 
glioblastoma patient specimens (31). After tumor removal, tissue was dissociated using 131 
a papain system (Worthington, New Jersey, USA) and a gentleMACS™ Dissociator 132 
(Miltenyi Biotec, Bergisch Gladbach, Germany). These cells were then maintained as 133 
suspension cultures in Neurobasal Medium with B-27 supplement (20 μl/ml) and 134 
Glutamax (10 μl/ml) from Invitrogen and fibroblast growth factor (FGF)-2, epidermal 135 
growth factor (EGF) (20 ng/ml each; Peprotech, Rocky Hill, Pennsylvania, USA) and 136 
heparin (32 IE/ml; Ratiopharm, Ulm, Germany). All cell lines were routinely tested for 137 
Mycoplasma using PCR (last test in december 2016). For all experiments described 138 
herein, the adherent cells were allowed to attach over a 24 h period. Subsequently, the 139 
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experiments were carried out in serum-free medium. KU-60019 (Selleckchem, Houston, 140 
Texas, USA) is a potent and specific ataxia-telangiectasia mutated (ATM) inhibitor, 141 
concentrations < 1.5 µM ensure specificity for ATM. TMZ, kindly provided by Schering-142 
Plough (Kenilworth, New Jersey, USA), was prepared in stock solutions (100 mM) in 143 
dimethylsulfoxide (DMSO). N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea (CCNU) was 144 
kindly provided by Medac (Wedel, Germany). Cells were irradiated using a cobalt-60 145 
source (Sulzer, Winterthur, Switzerland) and for different fractionations the 146 
approximative biological effective dose and dose per fraction according to the linear 147 
quadratic model (32) were determined using the R package ‘DVHmetrics’ (https://cran.r-148 
project.org/web/packages/DVHmetrics/index.html) under the assumption of an  ratio 149 
of 10 for human glioma cell lines. Thiazolyl blue tetrazolium bromide (MTT) was 150 
obtained from AxonLAb (Baden, Switzerland). 151 
 152 
Antibodies and flow cytometry 153 
The following monoclonal antibodies (mAbs) were used for the assessment of cell 154 
surface expression of MICA, MICB, ULBP2, ULBP3, RAE-1, MULT-1, H60 or blocking 155 
of NKG2D: MICA (AMO1, mouse IgG1), MICB (BMO1, mouse IgG1), ULBP2 (BUMO1, 156 
mouse IgG1), ULBP3 (CUMO3, mouse IgG1). Their generation has been described 157 
(33). RAE-1_FITC and MULT-1_PE and blocking anti-human NKG2D (clone 149810) 158 
were obtained from R&D Systems Europe (Abingdon, UK). H60_PerCP was obtained 159 
from Novus Biologicals (Littleton, Colorado, USA). Blocking but not depleting anti-160 
mouse NKG2D (clone C7) was obtained from eBioscience (San Diego, California, 161 
USA). As controls, we used isotype-matched antibodies from Sigma-Aldrich (Steinheim, 162 
Germany). The PE-conjugated goat anti-mouse IgG from Dako (Baar, Switzerland) was 163 
used as secondary antibody where appropriate. Cells were detached with Accutase 164 
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(Life technologies), preincubated in phosphate-buffered saline (PBS) with 2% FCS, and 165 
stained with speciﬁc mAbs (10 µg/ml) or matched mouse Ig isotype for 30 min on ice, 166 
followed by incubation with PE-conjugated secondary antibody for 30 min where 167 
appropriate. After washing, flow cytometric analyses were performed using a BD 168 
FACSVerse Analyzer (BD, Allschwil, Switzerland). In case of intracellular staining for 169 
ATMser1981 Fix/Perm Buffer Set from BioLegend (San Diego, California, USA) was used. 170 
For flow cytometric assessment of tumor-infiltrating lymphocytes, live/dead staining with 171 
FVS 510, anti-CD3_ PerCP-Cy5.5, anti-CD4_FITC, anti-CD8_APC-H7, anti-NKp46_PE, 172 
anti-IFN-_APC and anti-TCRȖ/δ_ BV4β1 from BioLegend (San Diego, California, USA) 173 
was used. Speciﬁc ﬂuorescence indexes (SFI) were calculated by dividing median 174 
ﬂuorescence obtained with the speciﬁc antibody by median ﬂuorescence obtained with 175 
isotype control antibody. For in vivo experiments fluorescence intensity was expressed 176 
as median fluorescence intensity. Data was analyzed with FlowJo software (Tree Star, 177 
Stanford, California, USA). 178 
 179 
Immune cell cytotoxicity assay 180 
We used a flow cytometry-based cytotoxicity assay to determine immune-mediated 181 
glioma cell lysis (34). Specific lysis was expressed as percentage of cell death of the 182 
PKH-26+ labeled targets. Percentage of target cell lysis was corrected for spontaneous 183 
background lysis by subtracting the percentage of dead cells in control samples (targets 184 
alone) from the percentage of dead cells within the test samples. As effector cells, we 185 
used either splenocytes isolated from mice, human NK cells isolated from PBMC by 186 
negative selection using NK cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, 187 
Germany) or NKL cells obtained from M.J. Robertson (Indiana University School of 188 
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Medicine, Indianapolis, Indiana, USA). For blocking experiments, NKL cells were 189 
preincubated for 2 h at 4°C with anti-NKG2D or IgG1 isotype control, and the antibody 190 
was also present during the co-incubation of target and effector cells. All experiments 191 
were done in triplicates. 192 
 193 
Real-time PCR 194 
Total RNA was isolated using the NucleoSpin RNA II system from Macherey-Nagel 195 
(Düren, Germany) and cDNA was prepared using the iScript cDNA Synthesis Kit from 196 
Bio-Rad Laboratories AG (Cressier, France). For real-time PCR, gene expression was 197 
measured in an ABI Prism 7000 Sequence Detection System (Applied Biosystems, 198 
Foster City, California, USA) with SYBR Green Master Mix (Thermo Fisher Scientific 199 
(Waltham, Massachusetts, USA) and primers (Microsynth AG, Balgach Switzerland) at 200 
optimized concentrations. Primers for MICA, MICB, ULBP2 and ULBP3 have been 201 
published (35). Primers used to detect murine NKG2DL were RAE-1 forward 5′-202 
TTTGGGAGCACAACCACAGAT-γ′, reverse 5′-TAAAGTTGGCGGGCTGAAAGA-γ′, 203 
MULT-1 forward 5′-CTGCCAGTAACAAGGTCCTTTC-γ′, reverse 5′-204 
GCTGTTCCTATGAGCACCAATG-γ′, H60a forward 5′-205 
CTGAGCTATCTGGGGACCATAC-γ′, and reverse 5′-AGTCTTTCCATTCACTGAGCAC-206 
γ′. As reference gene, we used human HPRT1: forward 5′-207 
TGAGGATTTGGAAAGGGTGT-γ′, reverse 5′-GAGCACACAGAGGGCTACAA-γ′ and 208 
mouse HPRT1: forward 5′- TTGCTGACCTGCTGGATTAC-γ′, reverse 5′- 209 
TTTATGTCCCCCGTTGACTG-γ′ respectively. The conditions were 40 cycles at 210 
95°C/15 s and 60°C/1 min. Standard curves were generated for each gene. Relative 211 
quantification of gene expression was determined by comparison of threshold values. 212 
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All results were normalized to HPRT1 and calculated with the ΔCTT method for relative 213 
quantification. 214 
 215 
Determination of cytotoxicity, acute cytostatic or clonogenic effects 216 
For determination of cytotoxicity, 5×103 cells were seeded per well in 96-well plates, 217 
allowed to attach for 24 h (adherent cells) and irradiated or exposed to TMZ, CCNU or 218 
staurosporine as indicated for 72 h in serum-free medium. Percentage of living cells 219 
was determined by flow cytometry after live/dead staining with Zombie Aqua™ Fixable 220 
Viability Kit (BioLegend, San Diego, California, USA). For acute growth inhibition 221 
assays, we used the same experimental setting but either crystal violet staining (for 222 
adherent cells) or MTT (for suspension cells) as read-out. Clonogenic survival assays 223 
were performed by seeding 102 cells per well in 96-well plates. After 24 h, the cells were 224 
irradiated or exposed to TMZ, CCNU, or staurosporine as indicated for 24 h in serum-225 
free medium, followed by observation for 20 days. As read-out methods, we used again 226 
either crystal violet staining or MTT. 227 
 228 
Immunoblot analyses 229 
For the detection of proteins in cell lysates, cells were lysed and processed as 230 
previously described (28). Thirty μg of protein were used per lane and visualization of 231 
protein bands was accomplished using horseradish peroxidase (HRP)-coupled 232 
secondary antibodies (Sigma-Aldrich) and enhanced chemiluminescence 233 
(Pierce/Thermo Fisher, Madison, Wisconsin, USA). 234 
 235 
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Immunofluorescence 236 
Cells were cultured in chamber slides with polystyrene-treated glass (BD Biosciences), 237 
fixed with 4% paraformaldehyde and permeabilized with 0.5% Triton X-100 (Sigma-238 
Aldrich). Blocking with 3% FCS was followed by incubation with anti-ATM protein kinase 239 
pS1981 monoclonal antibody (Rockland, Gilbertsville, Pennsylvania, USA) (diluted 240 
1:100) overnight at 4°C. Donkey anti-mouse IgG Alexa Fluor 488-labeled secondary 241 
antibody (Life technologies, Carlsbad, California, USA) was used at 1:200. Slides were 242 
mounted in Vectashield Mounting Media with DAPI (Burlingame, California, USA) and 243 
images were acquired by using a Leica TCS SP5 confocal microscope. 244 
 245 
Mice and animal experiments 246 
All experiments were done in accordance with the guidelines of the Swiss federal law on 247 
animal protection and they were approved by the cantonal veterinary office. C57BL/6 248 
mice were purchased from Charles River Laboratories (Sulzfeld, Germany). VM/Dk 249 
mice were bred in pathogen-free facilities at the University of Zurich. NKG2D-/- mice 250 
have been previously described (36) and were kindly provided by D. H. Busch (Munich, 251 
Germany). Mice of 6 to 12 weeks of age were used in all experiments in groups of 7-10 252 
mice. For intracranial tumor implantation SMA-560 cells (5 × 103) or GL-261 cells (2 x 253 
104) were stereotactically implanted into the right striatum at day 0. Mice were observed 254 
daily and sacrificed as indicated or in the survival experiments when developing 255 
neurologic symptoms. If indicated, local cranial radiotherapy with a single dose of 12 Gy 256 
was performed at day 10 after tumor implantation using a Gulmay 200 kV X-ray unit at 1 257 
Gy/min at room temperature. If indicated, mice received TMZ (10 mg/kg/day) per oral 258 
gavage from day 7-11 after tumor implantation. MRI was performed with a 4.7 T small 259 
animal magnetic resonance imager (Pharmascan; Bruker Biospin, Ettlingen, Germany) 260 
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at day 13 after tumor implantation. Coronal T2-weighted images were acquired using 261 
Paravision 6.0 (Bruker BioSpin). Mean +/- SD of the tumor volume in mm3 from 5 262 
mice/group were determined by the formula (length x width x depth)/2.  263 
For in vivo blockade of NKG2D signaling, mice were injected i.p. with 100 ug of the 264 
blocking but not depleting anti-NKG2D antibody (clone C7) (37) or with isotype control 265 
in PBS. Antibodies were given either one day before and one day after tumor 266 
implantation or at day 6 and 7 after tumor implantation and were re-injected every 7 267 
days until the mice were sacrificed. Time of antibody administration is indicated in the 268 
figure legends. 269 
Isolation of orthotopic tumor cells was performed on day twelve after tumor implantation. 270 
Brains were harvested after transcardial perfusion with ice-cold PBS to remove all 271 
circulating leukocytes from the CNS. Tumor cells were separated from myelin and red 272 
blood cells using a Percoll gradient suspension (Sigma-Aldrich). Cells were washed with 273 
PBS and stained with Zombie Aqua™ Fixable Viability Kit and fluoro-conjugated 274 
antibodies specific to indicated cell surface markers for flow cytometry.  275 
 276 
Tissue microarray of patient samples 277 
Studies were approved by the Institutional Review Board (KEK-StV-Nr.19/08) and 278 
informed consent was received prior to inclusion to the study. Twenty-one pairs of 279 
primary (before chemoradiation) and recurrent glioblastoma (variable timepoints after 280 
chemoradiation) specimens from patients who underwent brain tumor resection 281 
between 2000 and 2014 at the Department of Neurosurgery, University Hospital Zurich 282 
(Zurich, Switzerland) were collected. Immunohistochemistry was performed as 283 
described (31) using anti-MICA, anti-MICB, anti-ULBP2, or anti-ULBP3 antibodies from 284 
Sino Biological (Lucerna-Chem AG, Luzern, Switzerland) or anti-programmed death-285 
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ligand 1 (PD-L1) from Cell Signaling Technology (Danvers, Massachusetts, USA). 286 
Images were analyzed in an unsupervised and blinded fashion using TMARKER, a 287 
software toolkit for histopathological staining estimation (38).  288 
 289 
Statistical analysis 290 
Data are presented as means +/- SD. Experiments were repeated at least three times, if 291 
not indicated differently. Viability and acute and clonogenic cell growth studies were 292 
performed at least in triplicates. Statistical analyses were performed in GraphPad Prism 293 
(La Jolla, CA, USA) using multiple two-tailed Student’s t-tests and correction for multiple 294 
comparisons using the Holm-Sidak method. For analysis of tissue microarray data, we 295 
used Wilcoxon matched-pairs signed rank test. For analysis of heterogeneity of 296 
immunohistochemically stained NKG2DL, we calculated the intraclass correlation 297 
coefficient (ICC) (39) as a statistical measure to assess staining variation for 2 tissue 298 
cores from each tumor sample by using the R-package ‘ICC’ ( https://cran.r-299 
project.org/web/packages/ICC/index.html). Kaplan Meier survival analysis was 300 
performed to assess survival differences among the treatment groups and p values 301 
were calculated with Gehan-Breslow-Wilcoxon test. Throughout all figures, significance 302 
was concluded at *p < 0.05 and **p < 0.01. 303 
  304 
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Results  305 
 306 
TMZ induces NKG2DL expression in glioma cells independent from cytotoxic and 307 
growth inhibitory effects 308 
Exposure of glioma cells to TMZ has growth inhibitory as well as cytotoxic effects. To 309 
define the sensitivity of LN-18 and LN-229 cells to TMZ, we treated these cells with a 310 
broad range of TMZ concentrations and determined cell death, acute growth inhibition 311 
and clonogenic cell survival (Fig. 1A). Since NKG2DL are up-regulated in response to 312 
various stress stimuli, we explored in a next step whether TMZ induces the expression 313 
of NKG2DL in these cells. We observed an induction of several NKG2DL on mRNA and 314 
protein cell surface level over a wide concentration range (Fig. 1A, Suppl. Fig 1A-B) 315 
including low concentrations with minor cytotoxic and growth inhibitory effects as well as 316 
clinically relevant concentrations around plasma levels of 30-80 M of TMZ that are 317 
achieved in human patients (40). To evaluate the effect on other activating immune cell 318 
receptor ligand systems, we assessed CD112 and CD155 as ligands of the human 319 
DNAX accessory molecule-1 (DNAM-1, CD226) activating immune cell receptor. In 320 
contrast to NKG2DL, the cell surface expression of CD112 and CD155 was unaffected 321 
by TMZ (Suppl. Fig. 1C). Next, we examined the effect of TMZ on NKG2DL expression 322 
in GIC, a subpopulation of glioma cells with stem-like properties which are associated 323 
with resistance to chemotherapy and irradiation (41). S-24 cells were relatively resistant 324 
to TMZ with an EC50 value of 267 µM in clonogenic survival assays whereas ZH-305 325 
cells were more sensitive with an EC50 of 7.3 µM (Fig. 1B). TMZ induced several 326 
NKG2DL on mRNA and cell surface protein levels in both GIC lines. Again, there was 327 
no induction of DNAM-1 ligands (Suppl. Fig. 1D). Furthermore, we determined the 328 
expression of NKG2DL on mouse glioma cells and their induction by TMZ. GL-261 and 329 
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SMA-560 cells differed in their sensitivity to TMZ. The EC50 for clonogenic cell survival 330 
was ≈ 50 µM for GL-261 and >500 µM for SMA-560 (Fig. 1C). Similar to human cells, 331 
exposure to TMZ resulted in an up-regulation of NKG2DL in both murine glioma cell 332 
models. H60a is not expressed in C57BL/6 mice and the syngeneic GL-261 cells (42) 333 
and was therefore not detected in this cell line. 334 
To corroborate our findings that the upregulation of NKG2DL is not a general response 335 
pattern of glioma cells to cell death induction but rather a specific response to alkylating 336 
chemotherapy, we exposed LN-18 and LN-229 cells to different concentrations of 337 
staurosporine. Despite its strong effect on glioma cell viability, none of the NKG2DL was 338 
up-regulated by staurosporine (Suppl. Fig. 1E). However, CCNU, another alkylating 339 
agent commonly used in patients with recurrent glioblastoma (43) also induced 340 
NKG2DL already at low concentrations, close to those typically achieved in the plasma 341 
of patients (3.4-3.8 µM) (44) (Suppl. Fig. 1F). 342 
 343 
Irradiation induces NKG2DL in human and mouse glioma cells independent from 344 
cytotoxic and cytostatic effects 345 
Since radiotherapy belongs to the standard of care for glioma patients, we also 346 
assessed the effect of IR on NKG2DL expression in different glioma models. LN-18 347 
cells were more sensitive to irradiation than LN-229 cells with an EC50 value of 4 Gy vs. 348 
11 Gy in clonogenic survival assays. In both cell lines, IR induced the expression of 349 
several NKG2DL mRNA and cell surface protein (Fig. 2A). The induction of NKG2DL 350 
cell surface expression following IR was also confirmed when different fractionation 351 
schemes were applied (Suppl. Fig. 2A). Consistent with the TMZ data, there was no 352 
induction of DNAM-1 ligands upon irradiation (Suppl. Fig. 2B). In S-24 and ZH-305 GIC, 353 
irradiation had minor cytotoxic effects with an EC50 value of > 20 Gy but clear effects on 354 
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clonogenic survival with EC50 values ≈ 5 Gy. A clinically relevant single fraction in the 355 
range of 2-4 Gy increased NKG2DL mRNA and cell surface protein levels (Fig. 2B).  356 
We also confirmed the irradiation-mediated induction of NKG2DL in GL-261 and SMA-357 
560 mouse glioma cells. In both cell lines, irradiation upregulated NKG2DL on mRNA as 358 
well as on cell surface protein level (Fig. 2C).  359 
 360 
TMZ- but not irradiation-mediated NKG2DL induction is modulated by MGMT and 361 
both depend on ATM signaling 362 
MGMT promoter methylation predicts benefit from alkylating chemotherapy with TMZ in 363 
glioblastoma. To explore whether the TMZ-mediated induction of NKG2DL is influenced 364 
by MGMT, we used sub-cell lines of LN-18 with a stably silenced MGMT gene (30) or 365 
LNT-229 cells that stably overexpress MGMT (29). The modulation of MGMT 366 
expression affected the sensitivity to TMZ (Fig. 3A), but not to IR (Suppl. Fig. 3A). 367 
Furthermore, MGMT expression significantly decreased TMZ-mediated NKG2DL 368 
induction. This was demonstrated by an increased NKG2DL induction upon shRNA-369 
mediated MGMT silencing in LN-18 glioma cells that naturally express MGMT and a 370 
diminished NKG2DL induction in MGMT-overexpressing LNT-229 cells compared to 371 
MGMT-deficient wild-type LN-229 cells (Fig. 3B). The IR-mediated upregulation of 372 
NKG2DL was unaffected by the MGMT status (Suppl. Fig. 3B). Glioma cells can also 373 
acquire resistance to TMZ independent from MGMT expression. Mechanistically, this is 374 
linked, amongst others, to the down-regulation of DNA mismatch-repair proteins (28). 375 
Because this acquired resistance is a challenge in clinical practice that needs 376 
alternative treatment options, we assessed the induction of potentially immune-377 
activating NKG2DL in a glioma cell line with acquired TMZ resistance (28). Also in these 378 
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cells, TMZ or IR induced the cell surface protein level of NKG2DL. The same effect was 379 
observed after IR (Suppl. Fig. 3C, D). 380 
To elucidate the molecular mechanisms mediating the treatment-induced NKG2DL 381 
induction in glioma cells, we assessed the ATM pathway as part of the DNA damage 382 
response to genotoxic stress induced by TMZ (45). In LN-229 and S-24 cells, we 383 
detected an increase of active phospho-ATMSer1981 upon exposure to TMZ (Fig. 3C). 384 
Inhibition of ATM using RNA interference (Suppl. Fig. 3E) or KU-60019, a specific ATM 385 
inhibitor that inhibited ATM at 1.25 µM with little toxicity (Suppl. Fig. 3F), abrogated the 386 
TMZ-induced up-regulation of MICA and MICB in LN-229, S-24 cells (Fig. 3D). We 387 
confirmed this also for ZH-305 cells (Suppl. Fig. 3G). Furthermore, we observed this 388 
ATM-dependency also for irradiation-mediated NKG2DL induction (Fig. 3D, Suppl. Fig. 389 
3G). 390 
 391 
Exposure to TMZ and IR promote glioma cell immunogenicity in a NKG2D-392 
dependent manner 393 
To investigate functional effects of the TMZ- or RT-induced NKG2DL induction, we 394 
performed cytotoxicity assays using polyclonal human NK cells or NKL cells (46) as 395 
immune effectors. Pre-exposure of LN-229 or S-24 cells to TMZ resulted in an 396 
enhanced immune cell-mediated cytolysis (Fig. 4A, Suppl. Fig. 4A). In contrast, 397 
exposure of MGMT-overexpressing LNT-229 cells to TMZ at the same concentrations 398 
did not enhance immune-cell mediated cytolysis (Suppl. Fig. 4B). Pre-incubation of 399 
effector cells with blocking but not depleting anti-NKG2D antibodies abrogated the TMZ-400 
induced glioma cell susceptibility to immune cell killing (Fig. 4A). Similarly, LN-229 or S-401 
24 cells that were pre-irradiated with 2 Gy were more susceptible to immune cell-402 
mediated cytolysis in a NKG2D-dependent manner (Fig. 4B). 403 
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 404 
NKG2DL levels are increased in vivo in syngeneic glioma models following 405 
treatment with TMZ or IR as well as in human glioblastoma following 406 
radiochemotherapy  407 
To study the effect of TMZ and irradiation on glioma-associated NKG2DL in vivo, we 408 
generated GL-261_niRP and SMA-560_TurboFP650 mouse glioma cells, which stably 409 
express near-infrared fluorescent proteins and which are syngeneic to C57BL/6 or 410 
VM/Dk mice. This allowed for the detection of these cells by flow cytometry (Fig. 5A) 411 
and the specific assessment of NKG2DL protein levels on the cell surface ex vivo. After 412 
orthotopic tumor cell injection, we treated mice either with a single dose of local IR at 413 
day 10 or with TMZ per oral gavage for 5 consecutive days starting at day 7 after tumor 414 
cell inoculation. At day 12, mice were euthanized and the tumors explanted. TMZ and 415 
irradiation led to an up-regulation of NKG2DL in both orthotopic murine glioma cell 416 
models with a more pronounced effect in the SMA-560 model (Fig. 5A). 417 
To study the effect of chemo- and radiotherapy on glioma-associated NKG2DL in 418 
human glioblastoma patients, we created a tissue microarray (TMA) encompassing 21 419 
paired formalin-fixed samples of human glioblastoma specimens obtained before and 420 
after treatment with TMZ and/or radiotherapy. From 9 of these paired samples, we could 421 
also isolate RNA. Compared to basal expression, we detected increased levels of 422 
several NKG2DL on mRNA as well as on cell surface protein level after treatment with 423 
TMZ or IR or both (Fig. 5B). Based on 2 cores from each tumor, we found a 424 
heterogeneous expression of NKG2DL within tumors, particularly for ULBP2 and 425 
ULBP3 (Suppl. Fig. 5A). We did not observe correlations between NKG2DL and survival 426 
or NKG2DL and the immunosuppressive ligand PD-L1 in this small patient population. 427 
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There were also no significant differences in PD-L1 expression between primary and 428 
recurrent human glioblastoma samples (Suppl. Fig.  5B-D). 429 
 430 
The NKG2D system contributes to the therapeutic effects of TMZ and irradiation 431 
in glioma 432 
Finally, we asked whether the NKG2D system plays any role for the survival benefit 433 
gained from TMZ or irradiation in murine glioma models. We inhibited the NKG2D 434 
system in fully immune-competent, orthotopic SMA-560 glioma-bearing mice by 435 
repetitive intraperitoneal injections of a blocking but not depleting anti-NKG2D antibody 436 
(37). Its biological activity reflecting target inhibition was verified by decreased ex vivo 437 
cytolysis of SMA-560 cells upon TMZ exposure or irradiation by immune effector cells 438 
isolated from anti-NKG2D-treated mice (Suppl. Fig. 6A). At the treatment schedules 439 
used, either IR or TMZ prolonged survival, but this effect was more prominent for IR. 440 
Administration of the anti-NKG2D antibody abrogated the survival benefit conferred by 441 
TMZ and attenuated the IR-mediated survival benefit in SMA-560 glioma-bearing mice 442 
(Fig. 6A). This NKG2D-dependent effect of TMZ or IR in SMA-560 glioma-bearing mice 443 
was also present when the anti-NKG2D antibody was administered at day 6 and 7 post 444 
tumor implantation when tumors had already been established (Suppl. Fig. 6B). To 445 
confirm the importance of an intact NKG2D system for the efficacy of TMZ and IR in 446 
glioma in a second syngeneic setting, we used NKG2D knockout  447 
(NKG2D-/-) mice, as an even more robust model. These mice were treated with the 448 
same regimen of TMZ or IR. In addition, we also included the combination of both 449 
treatments, reflecting the current standard of care for human glioblastoma patients. 450 
There was no difference in median survival of glioma-bearing NKG2D-/- or NKG2D-intact 451 
mice when no treatment was administered. TMZ or irradiation prolonged the median 452 
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survival of GL-261 tumor-bearing mice and the combination of both therapies further 453 
increased the survival (Fig. 6B). However, the survival gain conferred by TMZ, 454 
irradiation or the combination of both was significantly reduced in NKG2D-/- mice (Fig. 455 
6B). The survival data were corroborated by MRI. At day 6 post tumor implantation we 456 
could not clearly delineate the tumor due to superimposing post-surgery alterations, but 457 
at day 13 post tumor implantation, we observed reduced activity of the anti-tumor 458 
treatments with regard to tumor growth in NKG2D-deficient mice (Fig. 6C, Suppl. Fig. 459 
6C). Finally, we analyzed tumor-infiltrating immune cells. TMZ alone significantly 460 
reduced NK and CD4 T cells, and IR as well as the combination of TMZ and IR reduced 461 
NK cells within the tumor microenvironment (Fig. 6D). There was no difference in the 462 
composition of tumor-infiltrating immune cells in NKG2D-/- versus NKG2D-intact mice. 463 
However, the activation status of infiltrating immune cells, which did not differ in 464 
untreated NKG2D-/- or NKG2D-intact mice, was impaired in NKG2D-/- mice upon 465 
treatment. NK cells as well as CD4 and CD8 T cells produced more IFN- in NKG2D-466 
intact mice following treatment with TMZ, IR or the combination of TMZ and IR, and this 467 
induction was attenuated in NKG2D-/- mice. In NKG2D-intact mice,  T cells produced 468 
more IFN-upon treatment with TMZ, IR or the combination of TMZ and IR compared to 469 
NKG2D-/- mice. In NKG2D-/- mice, we observed more IFN-production in  T cells only 470 
upon IR (Fig. 6D, Suppl. Fig. 6D-F). 471 
 472 
  473 
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Discussion  474 
 475 
TMZ chemotherapy and radiotherapy constitute the standard treatment modalities in 476 
patients with newly diagnosed glioblastoma (43). The anti-glioma effects of TMZ and IR 477 
comprise different molecular mechanisms such as induction of cell cycle arrest, 478 
senescence and apoptosis (47, 48). Furthermore, there is increasing evidence that cell 479 
death upon exposure to TMZ or IR can promote anti-tumor immune responses by 480 
releasing tumor-associated antigens or damage-associated molecular pattern 481 
molecules such as calreticulin, adenosine triphosphate or high-mobility group box 1 482 
protein (49-51). In addition to these soluble and potentially immune-stimulating 483 
molecules, glioma cells express membrane-bound ligands to the activating immune cell 484 
receptor NKG2D which basically enables target cell killing without prior sensitization and 485 
irrespective of MHC restriction.  486 
We observed an up-regulation of several NKG2DL on mRNA and protein level upon 487 
exposure to TMZ, CCNU or IR in several mouse and human glioma cells including 488 
stem-like cells (Fig. 1 and 2, Suppl. Fig. 1 and 2). NKG2DL induction by TMZ has 489 
previously been reported in four other human glioma cell lines (52). We found that the 490 
NKG2DL induction was independent from cytotoxic or growth inhibitory effects and was 491 
achieved at clinically relevant concentrations of chemotherapeutic agents and low 492 
doses of IR. Furthermore, we confirmed the up-regulation of NKG2DL on glioma cells 493 
upon treatment with TMZ or IR in vivo in two orthotopic mouse glioma models (Fig. 5A). 494 
The use of fluorescently labeled glioma cells excluded contaminating signals from 495 
immune cells which could also express NKG2DL (53). These findings were further 496 
corroborated by an analysis of paired samples of human glioblastoma tissue specimens 497 
obtained from patients during initial surgery and at tumor recurrence following radio- 498 
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and/or chemotherapy. The increased NKG2DL expression levels after alkylating 499 
chemotherapy or radiotherapy support our in vitro data as well as findings from the 500 
mouse studies (Fig. 5B). Changes in glioma cell NKG2DL levels may be confounded by 501 
other factors than treatment such as passenger mutations which occur during the 502 
course of the disease (54, 55). Despite these limitations, our data strongly suggest that 503 
NKG2DL expression levels are increased following radiochemotherapy. Together with 504 
the observation that NKG2DL can also be induced in TMZ-resistant cells (Suppl. Fig. 3C 505 
and D), this provides a rationale to investigate NKG2D-targeting therapies (27) also at 506 
tumor recurrence. 507 
We demonstrate that the up-regulation of NKG2DL upon TMZ or IR requires ATM (Fig. 508 
3D, Suppl. Fig. 3G) which supports the concept that the DNA damage response is one 509 
stimulus for the induction of NKG2DL (56). Consequently, ATM inhibitors may 510 
potentially counteract NKG2D-dependent anti-tumor immune effects. This needs to be 511 
considered in future trials evaluating the activity of such ATM inhibitors as 512 
radiosensitizers (57).  513 
Although the net effect of NKG2D ligand induction is of rather small magnitude, it has 514 
important functional consequences. The induction of NKG2DL by TMZ or IR enhanced 515 
the immunogenicity of glioma cells including GIC and rendered the cells more 516 
susceptible to immune-mediated cytolysis (Fig. 4, Suppl. Fig. 4A). Chemotherapy and 517 
radiotherapy have various effects on tumor cells and the microenvironment comprising 518 
both immune-stimulatory and immune-suppressive mechanisms. Our study indicates 519 
that treatment-associated NKG2DL induction constitutes a relevant immune-stimulatory 520 
mechanism because inhibition of NKG2D signaling abrogated the enhanced cytolysis. 521 
Furthermore, tumor-infiltrating NK, CD4, CD8 T cells and to some extent also  T cells 522 
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produced more IFN- in a NKG2D-dependent manner upon treatment with TMZ and/or 523 
irradiation (Fig. 6D). This emphasizes the relevance of the NKG2D-mediated immune-524 
stimulatory mechanism of TMZ and IR and adds another relevant mechanism to the 525 
concept of immunogenic cell death.   526 
We did not only demonstrate that TMZ- and radiotherapy-mediated NKG2DL induction 527 
can be used as a strategy to render glioma cells more immunogenic but also that the full 528 
efficacy of TMZ and IR against glioblastoma depends on an intact NKG2D system. The 529 
survival benefit gained with these treatment modalities was diminished upon blockade 530 
of NKG2D signaling with an inhibitory but non-depleting antibody or in NKG2D knockout 531 
mice (Fig. 6A and B, Suppl. Fig. 6A-C). Inhibition or deficiency of NKG2D in mice did 532 
not result in a significant survival difference without additional treatment, suggesting that 533 
the basal expression levels of NKG2DL are too low to promote a relevant immune 534 
response (7, 10, 26, 34, 58). 535 
The NKG2DL induction upon TMZ treatment or IR could provide a rationale for future 536 
studies investigating the synergistic application of these conventional treatment 537 
modalities with other NKG2D-based immunotherapeutic strategies (27). So far, one 538 
phase I study has used pure NK cells for adoptive immunotherapy in patients with 539 
recurrent malignant gliomas (59). However, no concomitant treatment with TMZ or IR 540 
was administered and additive or synergistic effects to this adoptive cell therapy need to 541 
be explored in future clinical trials.  542 
In summary, the present dataset demonstrates the relevance of a so far unrecognized 543 
mechanism mediating anti-tumor effects of TMZ and IR that is likely to be clinically 544 
relevant. Based on our findings, further studies evaluating the combination of 545 
radiochemotherapy with additional NKG2D-based immunotherapeutic strategies should 546 
be considered for the treatment of glioblastoma.  547 
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Figure legends 785 
 786 
Fig. 1. TMZ induces NKG2DL in human and mouse glioma cells including human 787 
GIC independent from cell death and growth inhibition. A LN-18 or LN-229 glioma 788 
cells were exposed to different concentrations of TMZ or DMSO control. Viability was 789 
assessed by live/dead staining at 72 h (black dotted line), cytostatic effects were 790 
detected by crystal violet staining at 72 h and 20 d (grey dashed and straight lines) (left 791 
panels). Transcripts for MICA, MICB, ULBP2 or ULBP3 were assessed by real-time 792 
PCR after 48 h (middle panels). Data represent mean values ± SD from 3 independent 793 
experiments (*p < 0.05; **p < 0.01). NKG2DL protein levels at the cell surface were 794 
determined by flow cytometry following exposure to TMZ or DMSO control for 72 h (right 795 
panels). Data are presented as SFI and mean values ± SD from 3 independent 796 
experiments are shown (*p < 0.05; **p < 0.01).  Grey areas represent TMZ plasma 797 
levels achieved in patients. B, C. S-24 or ZH-305 glioma-initiating cell lines (B) and GL-798 
261 or SMA-560 mouse glioma cells (C) were treated as indicated and human or murine 799 
NKG2DL were analysed as in (A).  800 
 801 
  Fig. 2. IR induces NKG2DL in human and mouse glioma cells independent from 802 
cell death and cell growth inhibition. A. LN-18 or LN-229 glioma cells were irradiated 803 
with different doses of gamma irradiation. Viability was assessed by live/dead staining 804 
(black dotted line), cytostatic effects were detected by crystal violet staining (grey 805 
dashed and straight lines) (left panels). Transcripts (MICA, MICB, ULBP2 or ULBP3) 806 
were assessed by real-time PCR after 48 h (middle). Data represent mean values ± SD 807 
from independent experiments (*p < 0.05; **p < 0.01). NKG2DL protein levels at the cell 808 
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surface were determined by flow cytometry 72 h after IR (right). Data are presented as 809 
SFI and mean values ± SD from 3 independent experiments are shown (*p < 0.05; **p < 810 
0.01). B, C. S-24 or ZH-305 glioma-initiating cell lines (B) and GL-261 or SMA-560 811 
mouse glioma cells (C) were irradiated as indicated and human or mouse NKG2DL 812 
were assessed as in (A). 813 
 814 
Fig. 3. NKG2DL induction is modulated by MGMT and depends on ATM. A. Whole 815 
cell lysates of LN-18_control or LN18_shMGMT cells and LN-229_control or LN-816 
229_MGMT were assessed by immunoblot for MGMT protein levels. Beta-actin was 817 
used as a control. Acute cytostatic and clonogenic effects after exposure to TMZ were 818 
determined by crystal violet staining at the indicated time points. B. The cells were 819 
exposed to TMZ and cell surface expression of MICA and MICB was determined after 820 
72 h by flow cytometry. Data are presented as SFI and mean +/- SD of 3 independent 821 
experiments is shown (*p < 0.05; **p < 0.01). C. LN-229 (left) or S-24 (right) cells were 822 
treated with KU-60019 or DMSO 4 h prior to TMZ exposure. Immunofluorescence 823 
images were acquired following pATMSer1981 staining (red). Nuclei are stained with 824 
DAPI (blue). D. LN-229 (left) or S-24 (right) were exposed to TMZ (upper row) or IR 825 
(lower panel) after ATM inhibition using KU-60019 or siRNA-mediated gene silencing. 826 
MICA and MICB cell surface expression were determined by flow cytometry. Data are 827 
presented as SFI and mean values ± SD from 2 independent experiments are shown 828 
(*p < 0.05; **p < 0.01). 829 
 830 
 831 
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Fig. 4. Exposure to TMZ or IR promotes glioma cell immunogenicity in a 832 
NKG2D-dependent manner. A. Upper panel: LN-229 (left) or S-24 (right) cells, pre-833 
exposed to TMZ (grey line) or DMSO control (black line) for 48 h, were used as 834 
target cells in a 3 h immune cell lysis assays using polyclonal NK (for LN-229) or 835 
NKL (for S-24) effector cells at various effector : target (E:T) ratios. Following TMZ 836 
treatment, viable glioma cells were counted before co-incubation with effector cells 837 
and immune-mediated cytolysis was corrected for spontaneous background lysis. 838 
Lower panel: NKL cells were pre-incubated with anti-NKG2D antibody or isotype 839 
control and subsequently used as effector cells in lysis assays with LN-229 or S-24 840 
glioma cells, either pre-exposed to TMZ or DMSO control, at an E:T ratio of 20:1. B. 841 
LN-229 or S-24 cells were irradiated with 2 Gy prior to use as target cells in 3 h lysis 842 
assays. The experimental setup was the same as in (A). In all figures mean +/- SD 843 
of triplicates from 1 representative out of 2 independent experiments is shown (*p < 844 
0.05; **p < 0.01).  845 
 846 
Fig. 5. TMZ and IR induce NKG2DL in vivo in syngeneic glioma models and 847 
human glioblastoma patients have increased tumor-associated NKG2DL after 848 
radiochemotherapy. A. Orthotopic tumor-bearing mice (SMA-560_TurboFP in 849 
VM/Dk mice (left) or GL-261_niRP in C57BL/6 mice (right)) received a single dose 850 
of local irradiation (12 Gy) on day 10 or TMZ (10 mg/kg/day) per oral gavage from 851 
day 7-11 after tumor implantation. Mice were sacrificed on day 12, tumors were 852 
dissociated and cells analyzed for NKG2DL cell surface expression by flow 853 
cytometry. Tumor cells were gated in the dot plot diagrams based on the fluorescent 854 
signal. Histograms represent mean fluorescence intensity of RAE-1, MULT-1 and 855 
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H60 on these cells. The diagrams summarize results of 5 mice per group. Data are 856 
presented as mean fluorescence intensity ± SD (*p < 0.05; **p < 0.01). B. NKG2DL 857 
were assessed on mRNA (upper panel) and surface protein level (lower panel) in 858 
matched pairs of human primary and recurrent tumors. Positive cell surface staining 859 
events were quantified in an unsupervised fashion with the TMARKER toolkit. (*p < 860 
0.05; ns = non-significant). 861 
 862 
Fig. 6. The NKG2D system contributes to the therapeutic effects of TMZ and 863 
IR in glioma. A. SMA-560 tumor-bearing mice received injections of anti-NKG2D 864 
or isotype control antibody one day before and one day and then every 7 days 865 
after tumor implantation. Subsequently, the animals were treated with TMZ or 866 
solvent control from day 7-11 or a single dose of IR at day 12. Survival data are 867 
presented as Kaplan-Meier plots (left and center). Combined analysis of median 868 
survival is plotted on the right. Survival differences were compared between 869 
different treatment groups (*p < 0.05; **p < 0.01) and within a treatment group 870 
between isotype or anti-NKG2D treatment (+p < 0.05; ++p < 0.01). B-D. GL-261 871 
tumor-bearing C57BL/6 or NKG2D-/- mice were treated with IR (single local dose of 872 
12 Gy at day 10), TMZ (10 mg/kg p.o., day 7-11) or the combination of both. B. 873 
Survival data are presented as Kaplan-Meier plots (left and center). Combined 874 
analysis of median survival of the different groups is plotted on the right (*p < 0.05; 875 
**p < 0.01 between treatment groups and +p < 0.05; ++p < 0.01 within a treatment 876 
group for intact NKG2D vs. NKG2D-/-). C. T2-weigthed coronal scans were 877 
acquired at day 13 after tumor implantation. Two representative scans for each 878 
group are shown (left). The white arrow marks the tumor region. Mean +/- SD of 879 
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the tumor volume in mm3 from 4 mice/group is shown (right). D. Percentage of NK, 880 
CD4, CD8, and  T cells (left) and the corresponding IFN- secretion (right) of 881 
tumor-infiltrating lymphocytes derived from mice described in B and C were 882 
determined at day 14 after tumor implantation. Mean +/- SD from 3 mice is shown 883 
(*p < 0.05; **p < 0.01 between treatment groups and +p < 0.05; ++p < 0.01 within 884 
a treatment group for intact NKG2D vs. NKG2D-/-). 885 
 886 
 887 






Supplementary Materials:
 Suppl. Fig. 1. Gating strategy for detection of cell surface NKG2DL. 
Representative data for LN-229 cells 72 h after treatment with different 
concentrations of TMZ is shown. Within the tumor cell population, we gated on 
single living cells. Cell surface expression after staining with isotype control, anti-
MICA, anti-MICB, anti-ULPB2, or anti-ULBP3 are displayed in histograms. Numbers 
in the upper right corners indicate the mean fluorescence intensity, which allows 
further calculation of speciﬁc ﬂuorescence indexes (SFI) by dividing median 
ﬂuorescence obtained with the speciﬁc antibody by median ﬂuorescence obtained 
with isotype control antibody. 
 
 
 
 
 
 
 
 
 
 
 
 Suppl. Fig. 2. DNAM-1 ligands are not induced upon treatment of TMZ or IR. CD112 
and CD155 protein levels at the cell surface of LN-18 or LN-229 cells (A) or S-24 or ZH-305 
(B) were determined by flow cytometry 72 h after exposure to TMZ or DMSO or single 
irradiation of LN-18 or LN-229 cells (C). Data are shown as SFI and median+/- SD from 3 
independent experiments is shown. 
Suppl. Fig. 3. Induction of NKG2DL is not an unspecific response to cell death induction in glioma 
cells. A. LN-18 (upper panel) or LN-229 (lower panel) cells were exposed to different concentrations of 
staurosporine. Viability was assessed by live/dead staining at 72 h (black line), cytostatic effects were 
detected by crystal violet staining at 72 h and 20 d (grey lines) (left panels). NKG2DL protein levels at the 
cell surface were determined by flow cytometry following exposure to staurosporine or DMSO control for 
72 h (right panels). Data are presented as SFI and mean values ± SD from 2 independent experiments are 
shown (*p < 0.05; **p < 0.01).  B. Same experimental setup as in A, but the cells were exposed to different 
concentrations of CCNU.
 
Suppl. Fig. 4. MGMT does not affect irradiation-induced NKG2DL expression and NKG2DL 
can be induced in glioma cells with acquired TMZ resistance A. LN-18_shMGMT and the 
corresponding LN-18_control cells or LN-229_MGMT and the corresponding LN-229_control 
cells were irradiated with increasing doses. Cell density was assessed by crystal violet staining 
after 72 h (acute cytostatic effect) or 20 days (clonogenic cell survival), respectively. B. On the 
cells described in A, cell surface expression of MICA and MICB was determined after 72 h by 
flow cytometry. Data are presented as SFI and mean values ± SD from 2 independent 
experiments are shown (*p < 0.05; **p < 0.01). C. LNT-229 cells with acquired resistance to TMZ 
or parental control cells were exposed to different concentrations of TMZ (upper panel, left graph) 
or doses of irradiation (upper panel, right graph). Cytostatic effects were detected by crystal violet 
staining at 72 h and 20 d. D. On the cells described in C, NKG2DL protein levels at the cell 
surface were determined by flow cytometry 72 h after exposure to TMZ (left graph) or irradiation 
(right graph). Data are presented as SFI and mean values ± SD from 2 independent experiments 
are shown (*p < 0.05; **p < 0.01).   
 
 
 
 
 
 
 
 
 
 
  
 
Suppl. Fig. 5. Inhibition of ATM in LN-229 or S-24 cells. LN-229 or S-24 cells were 
exposed to 1.25 µM of KU-60019 or siRNA oligonucleotides specific for ATM or scrambled 
control. After 72 h, the cells were stained with anti-phospho-ATMSer1981 PE antibody and 
assessed by flow cytometry. Data are presented as mean fluorescence intensity (indicated 
by numbers). 
 
 
 
 
 
 
  
Suppl. Fig. 6. Functional consequences of NKG2DL induction by TMZ or IR. A. Exposure 
to TMZ promotes immune-cell mediated glioma cell lysis. LN-229 cells, pre-exposed to TMZ 
(grey line) or DMSO control (black line) for 48 h, were used as target cells in a 3 h lysis assays 
using NKL effector cells at various effector : target (E:T) ratios. B. Blocking of NKG2D 
signaling with an inhibitory antibody in vivo. SMA-560 tumor-bearing mice that were treated 
with vehicle ctrl. (day 7-11), TMZ (day 7-11) or local IR (10 Gy at day 10) and received 
injections of anti-NKG2D or isotype control antibody one day before and every 7 days after 
tumor implantation. At day 14, splenocytes from these mice were used as effector cells in 
immune cell lysis assays. Target cells were SMA-560 cells pre-treated in vitro with TMZ, RT or 
not.  E:T was 20:1. As an additional control, splenocytes from non tumor-bearing, untreated 
mice were pre-treated ex vivo with blocking anti-NKG2D antibody and used as effector cells 
against the described target cells. C and D. Gating strategy for detection of tumor-infiltrating 
NK, CD4 and CD8 T cells. Fourteen days after tumor implantation, tumor-infiltrating 
lymphocytes were isolated after tumor dissociation and Percoll separation. NKp46+CD3- cells 
were determined as percentage of NK cells (C). Numbers indicate the percentage of positive 
cells. Furthermore, CD4 and CD8 positive cells were gated (D). Plots are representative for 
one out of three mice. 
 
 
